Beta Bionics, Inc
Beta Bionics, Inc is listed today as Beta Bionics, Inc.: market value, financials and filings are on its company page.
Funding rounds
4 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Aug 2023 | $100 M | No. 4 | $50 to $250 million | equity, options | SEC | |
| Feb 2022 | $57 M | No. 3 | $50 to $250 million | equity, options | SEC | |
| Jul 2019 | $63 M | No. 2 | $50 to $250 million | equity | SEC | |
| Dec 2017 | $58 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
As the listed company Beta Bionics, Inc., its revenue in fiscal 2025 came from these product and service lines: iLet $52.75 million (53%), Single-use Products $47.50 million (47%).
Annual report (SEC XBRL) · Dec 2025
Beta Bionics, Inc chose not to state its revenue in its newest notice of a funding round (Sep 2023).
SEC Form D · Sep 2023
The industry group it chose in its notices: Other Health Care.
SEC Form D · Sep 2023
Products and services#
No products or services of Beta Bionics, Inc are on record.
Investors#
2 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Mike Mensinger | Person | not stated | not stated | Held Series D preferred stock (Form 3, 2025) | SEC Form 3 |
| Wellington Hadley Harbor Aggregator IV, L.P. | Fund or asset manager | not stated | not stated | Held Series E preferred stock, 10% owner (Form 3, 2025) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 4 rounds above had up to 29 investors.
Largest shareholders today
Institutions holding Beta Bionics, Inc. shares, as of Sep 30, 2026.
- Price T Rowe Associates Inc /MD/$170 M16.45%
- Eventide Asset Management, LLC$134 M12.96%
- Morgan Stanley$82 M7.97%
- Sands Capital Alternatives, LLC$76 M7.35%
- Soleus Capital Management, L.P.$71 M6.89%
- BlackRock, Inc.$65 M6.28%
- Vanguard Capital Management LLC$42 M4.12%
- Deerfield Management Company, L.P.$36 M3.50%
- Jpmorgan Chase & Co$36 M3.45%
- Geode Capital Management, LLC$22 M2.09%
- First Light Asset Management, LLC$21 M2.04%
- Eversept Partners, LP$19 M1.88%
- State Street Corp$19 M1.88%
- RTW Investments, LP$19 M1.84%
- Point72 Asset Management, L.P.$18 M1.78%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Edward Damiano | Executive Chairman | Sep 2023 |
| Sean T. Saint | Chief Executive Officer | Sep 2023 |
| Stephen H. Feider | Chief Financial Officer, Secretary | Sep 2023 |
| Gibb Clarke | Chief Financial Officer | Mar 2022 |
| Marcie Cain | Chief People Officer | Mar 2022 |
| Martha Aronson | Interim Chief Executive Officer | Mar 2022 |
| Michael Pereira | Chief Operating Officer | Mar 2022 |
| Veena Rao | Chief Commercial Officer | Mar 2022 |
| Edward Raskin | Executive officer | Jul 2019 |
| Gilbert Clarke | Executive officer | Jul 2019 |
| Mike Roskino | Executive officer | Jul 2019 |
| Serafina Raskin | Executive officer | Jul 2019 |
| Edward B. Raskin | Executive officer | Oct 2018 |
| Edward R. Damiano | Executive officer | Oct 2018 |
| Gilbert H Clarke | Executive officer | Oct 2018 |
| Mike H Rosinko | Executive officer | Oct 2018 |
| Serafina H Raskin | Executive officer | Oct 2018 |
| Thomas A. Fitzgerald | Executive officer | Oct 2018 |
| Amanda T. Black | Director | Sep 2023 |
| Edward Damiano | Executive Chairman | Sep 2023 |
| Francesco T. Draetta | Director | Sep 2023 |
| Gilad T. Glick | Director | Sep 2023 |
| Lennox T. Ketner | Director | Sep 2023 |
| Parker T. Cassidy | Director | Sep 2023 |
| Sean D. Carney | Director | Sep 2023 |
| Sean T. Saint | Chief Executive Officer | Sep 2023 |
| Westley T. Dupray | Director | Sep 2023 |
| Beth Brooke | Director | Mar 2022 |
| Christy Jones | Director | Mar 2022 |
| Finny Kuruvilla | Director | Mar 2022 |
| Jeff Hitchcock | Director | Mar 2022 |
| Martha Aronson | Interim Chief Executive Officer | Mar 2022 |
| Sean Carney | Director | Mar 2022 |
| Adam Steensberg | Director | Jul 2019 |
| Agustin Mohedas | Director | Jul 2019 |
| Edward Raskin | Director | Jul 2019 |
| CHRISTIAN H Foged | Director | Oct 2018 |
| Deirdre B. Ibsen | Director | Oct 2018 |
| Edward B. Raskin | Director | Oct 2018 |
| Edward R. Damiano | Director | Oct 2018 |
Went public since 2025. Its SEC number is that of a company listed on a stock exchange.